C7orf26

Across TCGA pan-cancer cohorts, C7orf26 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of C7orf26’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where C7orf26 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types C7orf26 is over-expressed in tumor, although a few such as LUAD and COAD show the opposite, repressed pattern.

CCRCC, HNSC, and LUAD are the cancer types where C7orf26 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in C7orf26 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	+0.500	<.001	12	view →
HNSC	All	IV	+0.344	<.001	12	view →
LUAD	Male	II,III,IV	−0.284	<.001	7	view →
COAD	All	All	−0.167	.001	7	view →
LSCC	Male	All	+0.216	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

C7orf26–CCRCC

Open the CCRCC breakdown →